PROSTATE CANCER AND PROSTATIC DISEASES

Long-term oncologic outcomes of patients with grade group 1 prostate cancer and pT3a disease on final pathology

2026-07-17

Mohamad Watfa

Prostate Cancer and Prostatic Diseases, Published online: 17 July 2026; doi:10.1038/s41391-026-01138-z Long-term oncologic outcomes of patients with grade group 1 prostate cancer and pT3a disease on final pathology]]>

En-bloc vs lobe-by-lobe laser prostatectomy: where do we stand?

2026-06-24

Mahmoud Laymon

Prostate Cancer and Prostatic Diseases, Published online: 24 June 2026; doi:10.1038/s41391-026-01130-7 En-bloc vs lobe-by-lobe laser prostatectomy: where do we stand?]]>

Response to de Riese et al. regarding “methodological and clinical considerations of MRI-based prostate cancer risk calculators”

2026-06-22

Ciarán Courtney O’Toole

Prostate Cancer and Prostatic Diseases, Published online: 22 June 2026; doi:10.1038/s41391-026-01133-4 Response to de Riese et al. regarding “methodological and clinical considerations of MRI-based prostate cancer risk calculators”]]>

Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial

2026-06-20

Quoc-Dien Trinh

Prostate Cancer and Prostatic Diseases, Published online: 20 June 2026; doi:10.1038/s41391-026-01131-6 Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial]]>

Association between concomitant ACEI/ARBs use and survival of patients with prostate cancer receiving abiraterone acetate: A post-hoc analysis of two randomized trials

2026-06-12

Junliang Zhao

Prostate Cancer and Prostatic Diseases, Published online: 12 June 2026; doi:10.1038/s41391-026-01128-1 Association between concomitant ACEI/ARBs use and survival of patients with prostate cancer receiving abiraterone acetate: A post-hoc analysis of two randomized trials]]>

Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial)

2026-04-02

Santosh Gupta, Siyuan Guo, Susan Halabi, Chenxi Yu, Hyotae Kim, Jane McKenzie, Daniel J. George, David M. Nanus, Russell Z. Szmulewicz, Daniel C. Danila, Jun Luo, Emmanuel S. Antonarakis, Andrew J. Armstrong

Response to correspondence regarding “The value of micro-ultrasound for prostate cancer screening: a retrospective real-world feasibility study”

2026-03-26

Johann J. Wendler, Jonas Bechstein, Hannes Cash

Prostate Cancer and Prostatic Diseases, Published online: 26 March 2026; doi:10.1038/s41391-026-01112-9 Response to correspondence regarding “The value of micro-ultrasound for prostate cancer screening: a retrospective real-world feasibility study”

Risk factors for incidental prostate cancer following surgery for benign prostatic enlargement: A systematic review and meta-analysis

2026-03-23

Angelo Cormio, Akihiro Matsukawa, Alessandro Dematteis, Ahmed R. Alfarhan, Marcin Miszczyk, Navid Roessler, Abdulrahman S. Alqahtani, Stefano Mancon, Ichiro Tsuboi, Paweł Rajwa, Ugo Giovanni Falagario, Francesca Sanguedolce, Gian Maria Busetto, Carlo Bettocchi, Giuseppe Carrieri, Luigi Cormio, Andrea Benedetto Galosi, David D’Andrea, Takahiro Kimura, Shahrokh F. Shariat

Prostate Cancer and Prostatic Diseases, Published online: 23 March 2026; doi:10.1038/s41391-026-01108-5 Risk factors for incidental prostate cancer following surgery for benign prostatic enlargement: A systematic review and meta-analysis